Epidemiological analysis of 22 patients with congenital bleeding diathesis hospitalized in the Department of Maxillofacial Surgery in Lublin, Poland, 2008–2013

Jolanta Wojciechowicz¹, Anna Gawęda¹, Patryk Kasprzak¹, Bożena Sokołowska²,
Tomasz Tomaszewski¹

¹ Maxillofacial Surgery Department, Medical University, Lublin, Poland
² Haematoo oncology Department, Medical University, Lublin, Poland


Abstract

Introduction. Haemophilia A and B are congenital bleeding disorders caused by coagulation factor VIII or IX deficiency. Haemophilia A and B occur in men, like all qualities dependent on genes linked to gender, whereas women are asymptomatic carriers of the gene. The most dangerous manifestations of severe haemophilia include spontaneous haemorrhages into the joints, muscles and body cavities, haematuria and potentially very dangerous intracranial haemorrhages are also quite frequent. The most common manifestations in the region of the maxillofacial skeleton and oral cavity are recurring bleedings from the nose and the gums after dental extractions, as well as extensive haemorrhages from wounds after surgical procedures.

Objective. The aim of the study was the analysis of epidemiologic case records of 22 patients affected by various types of haemophilia, admitted to Maxillofacial Surgery Department at Medical University in Lublin, Poland, during 2008–2013.

Results. The most numerous group constituted patients diagnosed with Haemophilia A, followed by patients with von Willebrand disease and Haemophilia B, aged 21–40 years. The main cause of hospital admission was the need to perform complex oral cavity sanation. The patients were treated with factor VIII or Factor IX, FEIBA or Heamate P, depending on the type and severity of bleeding diathesis.

Key words

haemophilia, replacement therapy, oral cavity surgeries

INTRODUCTION

Haemophilia A (HA) and B (HB) are congenital bleeding diathesis caused by inhibition of coagulation factor VIII (FVIII) or IX (FIX). Haemophilia A and B occur in men, like all qualities dependent on genes and sex-related, while women are asymptomatic carriers [1, 2, 3]. Haemophilia A is diagnosed in 1 out of 5,000 male infants and haemophilia B in 1 out of 30,000 male infants [2, 4, 5]. Prevalence of Haemophilia A and B in Poland is estimated at 1:12300 inhabitants. In 30–50% of patients, mutation occurs spontaneously and there is no family history of the disease [5]. Since the clinical features of haemophilia A and B do not differ, the diagnosis is based on the deficient coagulation factor activity in plasma. There are three types of haemophilia: severe, moderate and mild: severe form – where the factor level is less than 1% of normal (<0.01 IU/ml); moderate form – where the factor level is 1–5% of normal (0.01–0.05 IU/ml); mild form – with the factor level more than 5–40% of normal (>0.05–0.40 IU/ml) [4].

The most dangerous manifestations of severe haemophilia include spontaneous bleeding into the joints, muscles and body cavities, haemorrhages into the joints, haematuria and menacing intracranial haemorrhages which are also quite frequent [1, 3, 5]. Bleedings that result from injuries or surgeries performed without the proper haemostatic protection. The diagnosis of haemophilia should include determining FVIII or FIX deficiency level in plasma, as well as identification of the causative mutation. Currently performed genetic tests detect the carrier state with 95% accuracy. The treatment of haemophilia encompasses increasing the activity of the deficient coagulation factor in blood circulation to stop or prevent active bleeding [3, 5, 7]. The following medications are currently used in the prophylaxis and treatment of haemophilia:

a) Lyophilized FVIII or FIX concentrate derived from plasma (plasma-derived concentrates), or recombinant concentrate produced in the genetic engineering processes (recombinant concentrates).

b) 1-deamino-8-D-arginine vasopressin (DDAVP) – desmopressin.

c) Medicines that inhibit fibrinolysis (antifibrinolytics) [1, 2, 4, 5].

Since intravenous infusions of 1 unit of FVIII per 1 Kg of body mass increase FVIII activity in plasma by approximately 2%, the following formula is used to estimate the proper dosage of FVIII: Dosage (units) = desired increase in FVIII activity in the patient’s plasma (%) x body mass BM (kg) x 0.5. Intravenous injections of FIX result in an increase of FIX activity in the patient’s plasma by 1%. The following formula is used: Dosage (units) = desired increase in FIX activity in the...
affected by the disease, and although the cause of the disease is identical, because in congenital haemophilia the clinical manifestations are different [2]. Diffuse subcutaneous bruises, mucosal haemorrhages, bleedings from surgical and dental extraction wounds, as well as diffuse and painful intramuscular hematomas, can be observed in acquired haemophilia. The annual incidence of acquired haemophilia is about 0.2–1 person per million inhabitants. The disease usually affects patients in the 6th–7th decade of their lives [2]. Patients with coexisting autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis (RA) and ulcerative enteritis, constitute quite a significant percentage of patients (20%). The most crucial medicines administered in patients affected by acquired haemophilia are activated prothrombin complex concentrate and recombinant active factor VII. The dosage of aPCC (activated prothrombin complex concentrate) and rFVIIa (recombinant activated factor VII) is identical to that in classical inhibitor complicated haemophilia [2, 6]. Imuno-suppressives are used to eliminate antibodies to FVIII. Oral dosage of prednison is 1mg/kg in monotherapy or combined with cyclophosphamide (CTX) in a daily dosage of 100–150 mg [2]. In patients affected by acquired haemophilia, APTT (activated partial thromboplastin time) is prolonged (2–3 times), with normal values of prothrombin, thrombin and bleeding time and correct number of plates and fibrinogen value [2]. Von Willebrand disease (VWD) has a prevalence of approximately 0.1% of the population, and is caused by deficiency or impairment of von Willebrand factor (VWF) – glikoprotein synthesised in angio-endothelium cells. There are three types of severity of von Willebrand disease, of which the most common manifestations include recurrent nose bleeds, mucosal haemorrhages and bleedings from skin wounds, and long-term and diffuse menorrhrea [2, 4]. Dental extractions and surgeries performed without haemostatic treatment usually result in profuse bleeding. Currently, two medicines: DDAVP and lyophilized concentrates of factor VIIIwith VWF, are used in the treatment of bleedings in VWD patients. Antifibrinolytics care is very useful in mucosal haemorrhages treatment [2, 4].

OBJECTIVE
The aim of the study is retrospective analysis of treatment procedures performed in 22 patients with various types of haemophilia admitted to the Maxillofacial Surgery Department at the Medical University in Lublin, Poland, during 2008–2013.

MATERIALS AND METHOD
The subjects of the study were haemophilic patients admitted to the Maxillofacial Surgery Department at Medical University in Lublin, Poland, during 2008–2013. The reasons for hospital admission – patients’ age, coexisting diseases, surgical procedures performed and replacement therapy patterns – were analysed. Statistica 10.0 PL software and Excell spreadsheets were used.
RESULTS

A total of 22 patients with diagnosed congenital haemorrhagic diathesis were treated at the Maxillofacial Surgery Department. The most numerous group were patients with Haemophilia A (15 persons), followed by patients with von Willebrand disease (5 persons), and finally, 2 patients with Haemophilia B.

Patients with the mild type of haemophilia (50%) dominated. Moderate type of haemophilia was diagnosed in 27.27% of patients, whereas 22.73% of patients were affected by severe haemophilia.

The largest group consisted of patients diagnosed with Haemophilia A (15 persons), with von Willebrand disease – 5 people, and 2 people diagnosed with Haemophilia B.

The most numerous group were patients with blood diathesis aged 21–40 years (40.91% of all patients admitted to hospital). The second group were patients aged over 60 (27.27%), whereas the least numerous group were patients aged 41–60 years (13.64%).

Coexisting diseases are the major problem in patients admitted to hospital, with hepatitis C (27.27%) as one of the leading ones. Patients also reported hypertension, gastric ulcers, asthma, gout and allergy (Fig. 6).

The average duration of hospitalization for patients with mild haemophilia was 4.09 days, for patients with moderate haemophilia – 5 days, and for patients with severe diathesis – 5.4 days (Fig. 7).

From the above diagram it may be concluded that only in the case of mild haemophilia could surgery be performed without coagulation factor replacement therapy. Complementary intravenous or oral treatment with Exacyl (tranexamic acid), subcutaneous, intravenous or nasal treatment with Minirin (desmopressin DDAVP), local surgical wound dressing with gelatine sponge Gelfoam or Surgical – plant-derived haemostatic – 100% oxidised regenerated, were used. The majority of patients admitted to hospital required...
Patients affected by congenital blood disorders have significantly lowered quality of life due to the problem of bleeding. Relatively simple dental procedures require proper preparation and post-operative management.

Treatment planning should involve liaison between the dental team and haemophilia care centres [10, 11]. According to Salem and Eshghi, maintaining restrictive oral hygiene that reduces the need for invasive dental procedures, as well as education concerning prophylaxis against dental caries and other oral diseases, are essential factors which improve the quality of life in all people, and especially children with coagulation disorders [9]. Nowadays, owing to high-purity coagulation factor concentrates, dental procedures can be performed in ambulatory care conditions. Anderson advises that in the case of lyophilized factor VIII or IX concentrates, dental procedures should be performed when the factor level varies from 30–50%; however, he points out that some European haemophilia care centres recommend a factor level ranging 60–80% [4]. Nevertheless, in properly treated patients with mild haemophilia, dental procedures that encompass bleeding can be performed in all dental surgeries on the condition that adjunct medications, such as Desmopressin (Minirin) or TA (Exacyl) that inhibit fibrinolysis, are administered. In the presented study, in 27.27% of hospitalized patients with mild haemophilia, it was not necessary to administer coagulation factors, only replacement therapy with the above-mentioned preparations was used.

Haemophilia A with inhibitors to factor VIII is a major therapeutic problem. It requires treatment with FEIBA (activated prothrombin complex concentrate–APCC in a dosage of 50–100 µg/kg BM body mass), or rFVIIa (recombinant active factor VII in a dosage of 70–90 µg/kg/body mass BM), and local haemostatic measures [1, 4, 12]. The future of haemophilia treatment is with PEGylated liposomes, which were used to synthesise factor VIII of prolonged efficacy [1, 6]. Research has shown that the efficacy of PEGylated liposomes is twice longer than classic factors which may enable reduction of the frequency of coagulation factors administration in the future. This has a key impact on the treatment of children since the number of intravenous punctures performed to administer factors is reduced, and the patients’ quality of life is improved.

In the 1960s, the main method of invasive dental treatment were procedures performed under general anaesthesia and transfusions of blood derivative preparations with coagulation factors. Having compared the above-dissertation with the study by Wojciechowich et al. [13], undertaken from 1981–2007, one can observe that several significant differences arise in the course of time, as well as advances in haemophilia treatment. The total number of patients with bleeding disorders admitted to the Maxillofacial Surgery Department in Lublin has definitely decreased, but patients affected by Haemophilia A still comprise the most numerous

The most often used adjuvant drug that increased blood clotting is Minirin (desmopressin DDAVP) in 3 patients and Exacyl (tranexamic acid) in 4 patients, mainly in mild haemophilia and less commonly in the moderate form of haemophilia.
group (154 patients in 1981–2007 and 15 patients in 2007–2013). Until 2007, cryoprecipitate and fresh frozen plasma were mainly used in replacement therapies. In 1991, factor VIII and IX concentrates appeared, and currently they are the standard treatment. The type of medical provision is another difference that can be observed. Owing to the National Bleeding Disorders Care Programmes (Haemophilia Care Centres), which also provide dental prophylaxis in patients up to the age of 18 years, oral hygiene has improved. However, in 1981–2007, the great majority of patients in the Maxillofacial Surgery Department in Lublin were children who required single or multiple deciduous tooth extractions, or were admitted due to profuse bleeding during primary or secondary dentition. From 2008–2013, no such cases were reported in the department and the greatest number of patients were aged 21–40 years and over the age of 60 (27.27%). Currently, the average duration of hospital treatment has shortened from 1 to 3 days in 54.5% of patients, compared to the previous years.

The number of patients with acute inflammations, such as dental abscesses, has decreased (only 1 case between 2008–2013). The use of antifibrinolytics and desmopressin in bleeding prophylaxis in haemophilic patients, enables performing minor dental procedures in dental surgeries without implementing coagulation factor treatment [14, 15, 16]. Transfusion-transmitted infections are a problem that emerged with plasma-derived concentrates treatment, although the risk of contaminating HCV, HBV and HIV through coagulation factors currently used in Poland is close to zero [5]. Nevertheless, according to the analysis conducted in Polish patients with severe haemophilia A and B born before 1991, about 80% are infected with HCV and about 10% with HBV [2].

Since 1980s, all blood derivative preparations have been checked for the presence of virus C. The infection is primarily present in elderly patients who might have been administered preparations contaminated by virus C when they were not checked previously for their presence [6, 10, 11]. The analysis confirmed this dependence since hepatitis C virus was diagnosed in 27.27% of hospitalized middle-aged and elderly patients.

The most recent change in the treatment of haemophilia which was introduced in Poland in 2008, involves prophylactic administration of factor VIII in all patients with severe haemophilia since birth in order to prevent haemophilic arthropathy caused by spontaneous haemorrhages into the joints. Moreover, ambulatory patients are given factor concentrate at home, and in the case of bleeding onset, they have the opportunity to infuse the preparation immediately [10].

**CONCLUSIONS**

1. The greatest percentage of haemophilic patients hospitalized in the Maxillofacial Surgery Department in Lublin during 2008–2013 comprised patients with mild haemophilia A, aged 21–40 years.
2. The main reason for hospital admission was the need to perform multiple extractions of numerous gangrenous teeth.
3. Concomitant diseases include hepatitis C (27.27% of hospitalized patients).
4. The average duration of hospitalization in more than half of the patients, mainly with mild haemophilia, was 1–3 days. The duration of hospitalization was longer in patients with severe haemophilia (up to 5.4 days).
5. Dental treatment planning should involve liaison between the dental team and a Haemophilia Care Centre.

**REFERENCES**